Kerydin effectively treats toenail onychomycosis in two phase 3 trials
“These studies demonstrate that [Kerydin (tavaborole, Anacor Pharmaceuticals, Inc).], a novel, first-in-class, boron-based pharmaceutical approved by the FDA for the treatment of toenail onychomycosis, has a favorable benefit-risk profile and is an attractive option for the treatment of onychomycosis of the toenail as a result of dermatophytes,” Boni E. Elewski, MD, of the University of Alabama at Birmingham, and colleagues wrote in their study.
UAB taps new surgeon-in-chief
After a national search, the University of Alabama at Birmingham has found a new surgeon-in-chief for its hospital and academic chair for its Department of Surgery.